

Bone Marrow and Stem Cell Transplantation Committee

Friday, October 13, 2023
10:30 AM - 12:00 PM CT

1. Active Protocol Updates

- a. SWOG1803 (Krishnan PI): Phase III Intergroup. Phase III Study of Daratumumab (NSC-791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy: Saurabh Chhabra. ALSO...Update on next intergroup trial: MajesTEC-4 Trial

2. New Trial Concept

- a. Randomized Trials of Total Marrow Irradiation as a Preparative Regimen for Acute Leukemias/High Grade MDS: Dr. Jeffrey Wong

3. Active Protocol Updates (continued)

- a. SWOG 2114 (Hess PI): Randomized Phase II Trial of consolidation therapy after an incomplete remission following commercial CAR-T cell infusion for relapsed/refractory DLBCL: Brian Hess/Nasheed Hossain, MD.
- b. ECOG A4151: Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission: Brian Till

4. Pending Trials

- a. SWOG 2213 (Hagen PI): Randomized trial of autologous stem cell transplantation for patients responding to induction therapy of Daratumumab-CyBorD for light chain amyloidosis: Patrick Hagen
- b. A161901 Alliance MyeloMATCH AML Tier 3 BMT consolidation/maintenance trial: Patrick Stiff; with discussion of RIC with venetoclax as part of transplant regimen and for first 100 days post-transplant: Dr Matthew Wieduwilt
- c. Randomized trial of autotransplant in CR1 for PTCL: Dr Marc Hoffman
- d. ECOG 4211 (Kenkre PI): Chemotherapy vs immunotherapy salvage therapy prior to autologous stem cell transplantation for relapsed/refractory Hodgkin's Lymphoma: Dr. Vaishalee Kenkre (Sairah Ahmed SWOG PI)